Stocklytics Platform
Asset logo for symbol ARVN
Arvinas
ARVN57
$8.43arrow_drop_down1.40%-$0.12
Asset logo for symbol ARVN
ARVN57

$8.43

arrow_drop_down1.40%
Key Stats
Open$8.55
Prev. Close$8.55
EPS-2.77
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.25
9.00
52 Week Range7.92
53.08
Ratios
EPS-2.77
Fundamentals
Payout Ratio-
Industry average yield2.92%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ARVN-
US Healthcare Sector-
US Market-
warning

ARVN / Market

ARVN lose to the US Market which returned 2.09% over the last twenty four hours.
warning

ARVN / Healthcare Sector

ARVN lose to the US Healthcare sector which returned 3.60% over the last twenty four hours.

Arvinas (ARVN) Statistics

Arvinas Inc (ARVN) is a biopharmaceutical company specializing in the development of targeted protein degradation therapies. The company utilizes its proprietary PROTAC® Platform to design small molecules that can selectively bind to disease-causing proteins and induce their degradation within cells. By targeting proteins that are traditionally considered 'undruggable,' Arvinas aims to revolutionize the treatment of various diseases, including cancer and neurodegenerative disorders.
With regards to INSTRUMENT_STATISTICS, Arvinas Inc's stock has experienced significant growth and volatility over the years. The company's valuation metrics reflect its potential in the biopharmaceutical industry. ARVN's fundamentals demonstrate its focus on innovation and commercialization of novel therapies.
add Arvinas  to watchlist

Keep an eye on Arvinas

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Arvinas (ARVN) stock's performance compared to its sector and the market over the past year?

Over the past year, Arvinas (ARVN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.50%, Arvinas has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.29%, it has fallen short of the market average. This comparison highlights Arvinas 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Arvinas (ARVN) stock?

The PE ratio for Arvinas (ARVN) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Arvinas (ARVN) stock?

The Earnings Per Share (EPS) for Arvinas (ARVN), calculated on a diluted basis, is -$2.77. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Arvinas (ARVN) stock?

The operating margin for Arvinas (ARVN) is -98.31%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Arvinas (ARVN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Arvinas (ARVN) is -$245.6M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Arvinas (ARVN) have?

Arvinas (ARVN) has a total debt of $9.7M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$90.8M.

Take Your Investments to a Whole New Level